FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study(†)

BACKGROUND: A targeted agent combined with chemotherapy is the standard treatment in patients with metastatic colorectal cancer (mCRC). The present phase III study was conducted to compare two doses of bevacizumab combined with irinotecan, 5-fluorouracil/leucovorin (FOLFIRI) in the second-line setti...

Полное описание

Сохранить в:
Библиографические подробности
Опубликовано в: :Ann Oncol
Главные авторы: Iwamoto, S., Takahashi, T., Tamagawa, H., Nakamura, M., Munemoto, Y., Kato, T., Hata, T., Denda, T., Morita, Y., Inukai, M., Kunieda, K., Nagata, N., Kurachi, K., Ina, K., Ooshiro, M., Shimoyama, T., Baba, H., Oba, K., Sakamoto, J., Mishima, H.
Формат: Artigo
Язык:Inglês
Опубликовано: Oxford University Press 2015
Предметы:
Original Articles
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC4478977/
https://ncbi.nlm.nih.gov/pubmed/25908603
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1093/annonc/mdv197
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы